B-cell Lymphoma is a rare, fast-growing cancer affecting white blood cells that help fight infections. This study tests the safety of a new drug, epcoritamab, used with other cancer-fighting medicines, in adults with Non-Hodgkin Lymphoma (NHL). Participants are divided into groups and given different treatment combinations. About 622 adults will take part globally. The study involves taking epcoritamab through a needle under the skin (subcutaneous) and other medicines by mouth (oral) or through a vein (intravenous). Treatments occur in cycles of 21, 28, or 56 days, based on the group. The study monitors treatment effects through medical check-ups, blood tests, and questionnaires.
- Participants must visit the hospital or clinic regularly.
- Different treatment combinations are based on eligibility.
- There may be more treatment demands than usual care.
How understandable was the trial content above?
Hard to understand
Easy to understand